Tiziana life sciences announces reduction in microglial activation in a total of 5 out of 6 intranasal foralumab expanded access patients with non-active secondary progressive multiple sclerosis

New york, june 05, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a reduction in microglial activation as seen in 3-month positron emission tomography (pet) scans that has now been seen in a total of 5 of the 6 patients with non-active secondary-progressive multiple sclerosis (na-spms) treated with intranasal foralumab in its expanded access program. activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, alzheimer's disease and amyotrophic lateral sclerosis (als).
TLSA Ratings Summary
TLSA Quant Ranking